Objective: The aim of this study was to investigate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the proportional growth of the fetus, maternal health, and neonatal outcomes.
Study Design: The study group (Group 1) included pregnant women with a history of COVID-19. Pregnant women who were hospitalized during the same period without COVID-19 were the control group (Group 2). Maternal and neonatal outcomes were compared between the groups.
Results: A total of 230 pregnant women and their infants were assessed. Group 1 ( = 74) had significantly higher rates of diabetes mellitus and hypertension than Group 2 ( = 156; = 0.015 and 0.014, respectively). Premature birth and cesarean section rates were also significantly higher in Group 1 than in Group 2 ( = 0.001 and 0.040, respectively). While the rate of iatrogenic preterm birth was significantly higher in Group 1, the rate of spontaneous preterm birth was significantly higher in Group 2 ( = 0.049). Infants born to COVID-19-positive mothers had lower median gestational age, birth weight, and Apgar scores ( < 0.01). There was no significant difference between the groups in terms of the results of cord blood gas analysis ( > 0.05). The rate of admission to the neonatal intensive care unit (NICU) and need for mechanical ventilation was significantly higher in infants of COVID-19-positive mothers ( < 0.05 for both). The length of stay in the NICU was also significantly longer for the infants of COVID-19-positive mothers ( < 0.05). Birth weights decreased due to increased cases of iatrogenic preterm births ( < 0.05). However, ponderal indices (PIs) of newborns of pregnant COVID-19 mothers did not differ at birth ( > 0.05).
Conclusion: COVID-19 is associated with low Apgar scores, increased risk of premature birth complications, and maternal comorbidities, with no effect on the PI and proportionate growth of the infant at birth.
Key Points: · No difference in ponderal indices.. · No difference in postnatal cardiovascular adaptation.. · COVID-19 is frequent in pregnant women with comorbidities like diabetes mellitus and hypertension..
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-0043-1777717 | DOI Listing |
Clin Trials
January 2025
Department of Medicine, Harvard Medical School, Boston, MA, USA.
Background/aims: People with disability have higher rates of cancer, excluding skin cancer, compared with people without disability. Food and Drug Administration draft guidelines from 2024 address use of performance status criteria to determine eligibility for clinical trials, advocating for less restrictive thresholds. We examined the exclusion of people with disability from clinical trials based on performance status and other criteria.
View Article and Find Full Text PDFAliment Pharmacol Ther
January 2025
Liver Unit, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Background And Aims: The laxative lubiprostone has been shown to decrease intestinal permeability. We aimed to assess the safety and efficacy of lubiprostone administered for 48 weeks in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Approach And Results: A randomised placebo-controlled trial was conducted in a specialised MASLD outpatient clinic at the National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
Eur J Breast Health
January 2025
Department of General Surgery, Elazığ Fethi Sekin City Hospital, University of Health Sciences Turkey, Elazığ, Turkey.
Objective: Triple negative breast carcinoma (TNBC) is characterized by the absence of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 receptor expression. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. The aim of this study was to investigate CA IX expression in TNBC and its relationship with treatment effect.
View Article and Find Full Text PDFMuscle Nerve
January 2025
Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
Background: Nusinersen and risdiplam are U.S. Food and Drug Administration (FDA)-approved treatments for spinal muscular atrophy (SMA).
View Article and Find Full Text PDFAnal Methods
January 2025
The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.
Human norovirus is the leading cause of non-bacterial gastroenteritis worldwide in all age groups. In this study, a rapid, high-sensitivity and quantitative detection method for VP1 protein of norovirus GII was developed based on time-resolved fluorescence microsphere immunochromatography. The optimal labeling amount and coated antibody concentration of norovirus monoclonal antibody were 10 μg and 1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!